01—Abstract
Summary
Summary of the 8-K filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
CVS Health reported strong second-quarter 2026 results, with total revenues of $106.1 billiona (up 7.3% year-over-year), GAAP diluted EPS of $2.31 (versus $0.80), and Adjusted EPS of $2.58 (versus $1.81).
The improvement was driven mainly by the Health Care Benefits segment, where adjusted operating income rose 85.5% to $2.4 billionb and the medical benefit ratio improved 250 basis points to 87.4%. The comparison is also flattered by the absence of $833 million in legacy litigation charges and a $471 million Group Medicare Advantage premium deficiency reserve recorded in the prior-year quarter. Consolidated adjusted operating income rose 35.4% to $5.2 billion, with all three operating segments contributing growth.
Management raised full-year 2026 guidance: GAAP diluted EPS to $6.84c–$7.04 (from $6.24–$6.44), Adjusted EPS to $7.90–$8.10 (from $7.30–$7.50), and cash flow from operations to at least $11.5 billion (from at least $9.5 billion). The raise reflects gains in Health Care Benefits and Pharmacy & Consumer Wellness, while management kept a cautious stance for the rest of the year citing elevated cost trends and possible macro headwinds. Year-to-date operating cash flow was $10.6 billion, and the Health Care Benefits segment's Commercial premium revenue fell 19.7%, reflecting the exit from the individual exchange business.
The quarter shows meaningful margin recovery in managed care, while Health Services and Pharmacy & Consumer Wellness delivered steadier, lower-growth earnings. Investors should weigh the strength of the reported improvement against the cautious tone on the back half and the fact that much of the year-over-year gain reflects lapping prior-year charges. Note that the 8-K itself is a furnishing of the earnings release under Item 2.02 and is not deemed filed under the Exchange Act.
02—Key points
Key Highlights
- Total revenues of $106.1B, up 7.3% YoY, with growth across all operating segments.
- GAAP diluted EPS of $2.31 vs. $0.80 a year ago; Adjusted EPS of $2.58 vs. $1.81 (up 42.5%).
- Health Care Benefits adjusted operating income rose 85.5% to $2.43B; MBR improved 250 bps to 87.4%, aided by absence of a $471M premium deficiency reserve.
- Full-year 2026 guidance raised: GAAP EPS to $6.84–$7.04, Adjusted EPS to $7.90–$8.10, operating cash flow to at least $11.5B.
- Prior-year quarter included $833M in legacy litigation charges, which inflates the year-over-year GAAP operating income increase of 97.5%.
- Health Care Benefits prior-year reserve development was favorable by $1.2B in the first half of 2026, a potential source of earnings quality questions.
- Management remains cautious for the rest of 2026 citing elevated medical cost trends and macro risks; cash and equivalents rose to $11.3B, and debt was reduced by roughly $3.3B in the first half.
03—Questions
Frequently Asked Questions
Why did CVS's earnings improve so much year over year?
The largest driver was the Health Care Benefits segment, where adjusted operating income rose 85.5% on better underlying Government business performance and an MBR improvement of 250 bps. The comparison also benefits from the prior-year quarter, which carried $833M of legacy litigation charges and a $471M Group Medicare Advantage premium deficiency reserve. Those items were absent in Q2 2026.
Did CVS raise its full-year 2026 outlook?
Yes. GAAP diluted EPS guidance rose to $6.84–$7.04 from $6.24–$6.44, Adjusted EPS guidance rose to $7.90–$8.10 from $7.30–$7.50, and operating cash flow guidance rose to at least $11.5B from at least $9.5B. Management said the outlook remains cautious for the rest of the year given elevated cost trends.
How is the Health Care Benefits membership and business mix changing?
Total medical membership was 26.0 million, roughly flat versus March 31, 2026 but down from 26.7 million a year earlier. Commercial premium revenue fell 19.7% year over year, reflecting the exit from the individual exchange business, while Government premium revenue grew 9.9%.
Are the Q2 earnings driven by one-time or favorable items?
Partly. Adjusted EPS excludes amortization of intangibles, realized capital losses, and integration costs, which are recurring in nature for an acquisitive company. The first half also included $1.2B of favorable prior-year health care cost development in Health Care Benefits, which supports reported results but is not repeatable indefinitely.
Is this 8-K a formal financial statement filing?
No. The 8-K furnishes the Q2 2026 earnings press release (Exhibit 99.1) under Item 2.02. The information is furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated into Securities Act filings unless specifically referenced. Investors should rely on the 10-Q for audited-quality detail and formal disclosures.
04—Continue